| Literature DB >> 28298488 |
Quentin Defenouillère1,2, Abdelkader Namane1, John Mouaikel1, Alain Jacquier1, Micheline Fromont-Racine3.
Abstract
Protein quality control mechanisms eliminate defective polypeptides to ensure proteostasis and to avoid the toxicity of protein aggregates. In eukaryotes, the ribosome-bound quality control (RQC) complex detects aberrant nascent peptides that remain stalled in 60S ribosomal particles due to a dysfunction in translation termination. The RQC complex polyubiquitylates aberrant polypeptides and recruits a Cdc48 hexamer to extract them from 60S particles in order to escort them to the proteasome for degradation. Whereas the steps from stalled 60S recognition to aberrant peptide polyubiquitylation by the RQC complex have been described, the mechanism leading to proteasomal degradation of these defective translation products remains unknown. We show here that the RQC complex also exists as a ribosome-unbound complex during the escort of aberrant peptides to the proteasome. In addition, we identify a new partner of this light version of the RQC complex, the E3 ubiquitin ligase Tom1. Tom1 interacts with aberrant nascent peptides and is essential to limit their accumulation and aggregation in the absence of Rqc1; however, its E3 ubiquitin ligase activity is not required. Taken together, these results reveal new roles for Tom1 in protein quality control, aggregate prevention, and, therefore, proteostasis maintenance.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28298488 PMCID: PMC5415013 DOI: 10.1091/mbc.E16-10-0746
Source DB: PubMed Journal: Mol Biol Cell ISSN: 1059-1524 Impact factor: 4.138
FIGURE 1:The RQC complex binds aberrant peptides in both 60S cosedimenting fractions and light fractions. (A) Sedimentation profile (absorbance at 260 nm) of a 10–50% sucrose gradient fractionation of TAP-NonStop affinity-purified complexes in ski2Δ cells depleted of Cdc48. The proteins contained in each fraction were monitored by acrylamide gel migration and silver nitrate staining. (B) The proteins associated to the TAP-NonStop complexes cosedimenting with the 60S, the 80S, and fractions 4 and 5 of the gradient were identified and quantified by LC-MS/MS. Comparison of the LFQ intensities of each protein between the 60S and 80S fractions. Each dot indicates an identified and quantified protein. The black star refers to the TAP-NonStop bait. (C) Comparison between proteins identified in fractions 4and 5 with 80S fractions. This purification coupled with gradient fractionation was repeated six times, and all LC-MS/MS analyses yielded comparable results. The list of proteins identified is given in Supplemental Dataset S1.
FIGURE 2:The RQC complex specifically interacts with aberrant nascent peptides in light-sedimenting fractions. (A) Silver-staining analysis of the proteins purified and fractionated from TAP-Stop (left) vs. TAP-NonStop (right) purifications upon Cdc48 depletion. (B) The proteins sedimenting in fractions 4 and 5 for both purifications were analyzed and quantified by LC-MS/MS. Comparison of LFQ intensities of all proteins identified in fractions 4 and 5 between the two purifications. The dots correspond to identified proteins, and the black star refers to the TAP-Stop or the TAP-NonStop baits (the four gray dots in the vicinity of the black star correspond to the contaminant proteins Pgk1, Act1, Pdb1, and Ssa1). The purifications using the TAP-Stop and TAP-NonStop reporters were repeated twice. The list of proteins identified is given in Supplemental Dataset S1.
FIGURE 3:Rqc1 cosediments in light-sedimenting fractions in the absence of Rqc2, Ltn1, or Cdc48. Sedimentation profile (absorbance 260 nm) and Western blots performed with polysome extracts prepared from cells expressing Rqc1-TAP with a wild-type background, deleted for LTN1 or RQC2 or depleted for Cdc48, separated on 10–30% sucrose gradients. The localization of Rqc1-TAP was assessed using PAP antibodies; the 60S fractions and the Cdc48-sedimenting fractions were determined with anti-Nog1 and anti-Cdc48 antibodies, respectively.
FIGURE 4:Tom1 interacts significantly with the light-sedimenting RQC complex. (A) Silver-staining analysis of the proteins fractionated from Rqc1-TAP (right) vs. negative control (left) purifications upon Cdc48 depletion. (B) Proteins associated with Rqc1-TAP complexes cosedimenting with fractions 4 and 5 (left) or the 60S (right) were identified by LC-MS/MS, and t tests of LFQ intensities for each protein were performed in comparison with the negative control. Statistical results are given in the form of volcano plots. The x-axis shows the log2 of LFQ ratios between the samples, and the y-axis shows the –log10 of the p value of each protein enrichment among statistical groups. The semicircular curve defines candidates that are significantly enriched according to a statistical t test. These purifications coupled with gradient fractionation were repeated four times. The list of proteins identified is given in Supplemental Dataset S1.
FIGURE 5:The interaction between Tom1 and the light RQC complex is Rqc2 independent but requires Ltn1. (A) Silver-staining analysis of TEV eluates purified from an Rqc1-TAP genomic fusion in various mutant strains (wild-type, rqc2Δ, and ltn1Δ) with or without Cdc48 depletion. (B) Proteins enriched with Rqc1-TAP purifications upon Cdc48 depletion were identified by LC-MS/MS, and t tests of LFQ intensities for each protein were performed in comparison with an untagged strain (negative control). Statistical results are presented in the form of a volcano plot. The x-axis shows the log2 of LFQ ratios between Rqc1-TAP and the control, and the y-axis shows the –log10 of the p value of each protein enrichment among statistical groups. The semicircular curve defines the candidates that are significantly enriched according to a statistical t test. (C) Mass spectrometry analyses of proteins identified in Rqc1-TAP purifications upon Cdc48 depletion, with or without a deletion of LTN1. Comparison of LFQ intensities obtained for each protein in the two samples; each dot represents an identified protein. (D) Comparison of Rqc1-TAP purification upon Cdc48 depletion, with or without a deletion of RQC2. The purifications presented in B were performed four times each, and those in C and D were performed once. The list of proteins identified is given in in Supplemental Dataset S1.
FIGURE 6:The RQC-Tom1 interaction relies on the polyubiquitylation activity of Ltn1. (A) Silver-staining analysis of TEV eluates purified from Rqc1-TAP–expressing cells in various mutant strains (wild-type, ltn1Δ, ltn1ΔRING, and tom1Δ) upon Cdc48 depletion. (B) LC-MS/MS analyses of proteins identified in Rqc1-TAP purifications upon Cdc48 depletion, with and without a deletion of the RING domain of LTN1. Comparison of LFQ intensities obtained for each protein in the two samples; each dot represents an identified protein. These purifications were performed once, except for the ltn1Δ mutant purification, which was performed twice. The list of proteins identified is given in Supplemental Dataset S1.
FIGURE 7:Tom1 physically interacts with aberrant nascent peptides in vivo in the absence of SKI2 upon Cdc48 depletion. (A) Proteins enriched with Tom1-TAP purifications (TEV eluate) upon Cdc48 depletion and deleted for SKI2 were separated on 4–12% gradient polyacrylamide NuPAGE gel and silver stained. For comparison, a fraction of total cellular extracts (input) was loaded. (B) Western blots were performed with input and TEV eluates fractions as in A. The presence of the 3XFlag-His3-NS aberrant peptides was assessed using anti-Flag antibodies. Tom1-CBP bait was probed with a CBP antibody. Anti-Rpl1 antibody was used to reveal Rpl1 ribosomal protein, and polyubiquitylated proteins were assessed with anti-ubiquitin antibodies. (C) Tom1 cosediments in light-sedimenting fractions. Western blots were performed with polysome extracts prepared from cells deleted for SKI2, depleted of Cdc48, and separated on 10–50% sucrose gradients. Tom1-TAP was assessed using PAP antibodies. The 40S and 60S fractions were determined with anti Rps8 and anti-Nog1 antibodies, respectively.
FIGURE 8:Tom1 becomes essential to limit aberrant protein aggregation when Rqc1 is impaired. (A) Western blots performed with polysome extracts prepared from TAP-NonStop–expressing cells in a wild-type background or deleted for RQC1, TOM1, or both, and separated on 10–50% sucrose gradients. The sedimentation profiles of aggregated (stacking gel) and soluble TAP-NonStop were assessed using PAP antibodies, and the 60S cosedimenting fractions were probed using anti-Nog1 antibodies. (B) As in A, using TAP-NonStop–expressing cells deleted for RQC1 and RQC2 (left) or RQC1, RQC2, and TOM1 (right).
FIGURE 9:Tom1 prevents the expansion of cytosolic protein aggregates in the absence of Rqc1. WT, tom1Δ, rqc1Δ, and rqc1Δtom1Δ strains expressing the GFP-NonStop reporter protein were analyzed by fluorescence microscopy. Left, yeast cells (Nomarski); second and third sets of images, GFP and Hoechst fluorescence signals, respectively; right, their merge. Scale bar, 5 μm.
FIGURE 10:The E3 ubiquitin ligase activity of Tom1 is not required for its role in protein aggregate prevention. (A) Western blots performed with polysome extracts prepared from tom1Δ, rqc1Δ, rqc1Δtom1Δ, and rqc1Δtom1Δltn1Δ mutant cells and separated on 10–50% sucrose gradients. The sedimentation profiles of ubiquitylated proteins in their aggregated form (stacking gel) were assessed using anti-ubiquitin antibodies. The 60S cosedimenting fractions were probed using anti-Nog1 antibodies. (B) Western blots were performed using total protein extracts and polysome extracts separated on 10–50% sucrose gradients (for which the light-sedimenting fractions [SC] and the 60S-sedimenting fractions were respectively pooled), prepared from rqc1Δ, rqc1Δtom1Δ, and rqc1Δtom1-C3235A mutant yeast cells expressing the TAP-NonStop reporter. The sedimentation profiles of the aggregated and soluble versions of the TAP-NonStop reporter were probed with PAP antibodies (middle), and the levels of aggregated polyubiquitylated proteins were assessed with anti-ubiquitin antibodies (top). Anti-G6PDH antibodies were used as a loading control (bottom).
Yeast strains used in this study.
| Strain | Genotype | Reference |
|---|---|---|
| BY4741 | ||
| BY4742 | ||
| LMA1951 | as BY4741, | |
| LMA2688 | as BY4741, | |
| LMA2689 | as BY4741, | |
| LMA2648 | as BY4741, | This study |
| LMA2869 | as BY4741, | This study |
| LMA2870 | as BY4741, | This study |
| LMA3002 | as BY4741, | This study |
| LMA3058 | as BY4741, | This study |
| LMA4747 | as BY4741, | |
| LMA4748 | as BY4741, | This study |
| LMA4750 | as BY4741, | This study |
| LMA4752 | as BY4741, | This study |
| LMA2773 | as BY4741, | |
| LMA3006 | as BY4741, | This study |
| LMA4806 | as BY4741, | This study |
| LMA1967 | as BY4742, | |
| LMA2070 | as BY4741, | |
| LMA2714 | as BY4741, | |
| LMA2948 | as BY4742 | This study |
| LMA3123 | as BY4742 | This study |
| LMA3202 | as BY4742 | This study |
| LMA3193 | as BY4742 | This study |
| LMA2135 | as BY4742, | |
| LMA3645 | as BY4742, | This study |
| LMA2719 | as BY4742, | |
| LMA2746 | as BY4742, | |
| LMA3121 | as BY4742, |